Prioritizing precision medicine for prostate cancer (English)
- New search for: Attard, G.
- New search for: Beltran, H.
- New search for: Attard, G.
- New search for: Beltran, H.
In:
ANNALS OF ONCOLOGY
;
26
, 6
;
1041-1042
;
2015
-
ISSN:
- Article (Journal) / Print
-
Title:Prioritizing precision medicine for prostate cancer
-
Contributors:Attard, G. ( author ) / Beltran, H. ( author )
-
Published in:ANNALS OF ONCOLOGY ; 26, 6 ; 1041-1042
-
Publisher:
- New search for: OXFORD UNIVERSITY PRESS
-
Publication date:2015-01-01
-
Size:2 pages
-
ISSN:
-
Type of media:Article (Journal)
-
Type of material:Print
-
Language:English
- New search for: 616.992
- Further information on Dewey Decimal Classification
-
Classification:
DDC: 616.992 -
Source:
© Metadata Copyright the British Library Board and other contributors. All rights reserved.
Table of contents – Volume 26, Issue 6
The tables of contents are generated automatically and are based on the data records of the individual contributions available in the index of the TIB portal. The display of the Tables of Contents may therefore be incomplete.
- 1041
-
Prioritizing precision medicine for prostate cancerAttard, G. / Beltran, H. et al. | 2015
- 1043
-
Determining the indications for post mastectomy radiotherapy: moving from 20th century clinical staging to 21st century biological criteriaRussell, N. S. / Kunkler, I. H. / van Tienhoven, G. et al. | 2015
- 1045
-
Does interim PET increase the value of ABVD in advanced-stage Hodgkin lymphoma?Gallamini, A. / Kostakoglu, L. et al. | 2015
- 1048
-
Assessing response to treatment of bone metastases from breast cancer: what should be the standard of care?Woolf, D. K. / Padhani, A. R. / Makris, A. et al. | 2015
- 1058
-
Approach to therapy of diffuse large B-cell lymphoma in the elderly: the International Society of Geriatric Oncology (SIOG) expert position commentaryMorrison, V. A. / Hamlin, P. / Soubeyran, P. / Stauder, R. / Wadhwa, P. / Aapro, M. / Lichtman, S. M. et al. | 2015
- 1069
-
Genetic lesions in diffuse large B-cell lymphomasTestoni, M. / Zucca, E. / Young, K. H. / Bertoni, F. et al. | 2015
- 1081
-
Recent developments in the prevention of chemotherapy-induced nausea and vomiting (CINV): a comprehensive reviewJordan, K. / Jahn, F. / Aapro, M. et al. | 2015
- 1091
-
The prevalence and outcomes of frailty in older cancer patients: a systematic reviewHandforth, C. / Clegg, A. / Young, C. / Simpkins, S. / Seymour, M. T. / Selby, P. J. / Young, J. et al. | 2015
- 1101
-
Visceral adiposity and colorectal adenomas: dose-response meta-analysis of observational studiesKeum, N. / Lee, D. H. / Kim, R. / Greenwood, D. C. / Giovannucci, E. L. et al. | 2015
- 1110
-
Integrative molecular profiling of routine clinical prostate cancer specimensGrasso, C. S. / Cani, A. K. / Hovelson, D. H. / Quist, M. J. / Douville, N. J. / Yadati, V. / Amin, A. M. / Nelson, P. S. / Betz, B. L. / Liu, C. J. et al. | 2015
- 1118
-
EVERSUN: a phase 2 trial of alternating sunitinib and everolimus as first-line therapy for advanced renal cell carcinomaDavis, I. D. / Long, A. / Yip, S. / Espinoza, D. / Thompson, J. F. / Kichenadasse, G. / Harrison, M. / Lowenthal, R. M. / Pavlakis, N. / Azad, A. et al. | 2015
- 1123
-
First-line treatment with sunitinib for type 1 and type 2 locally advanced or metastatic papillary renal cell carcinoma: a phase II study (SUPAP) by the French Genitourinary Group (GETUG)†Ravaud, A. / Oudard, S. / De Fromont, M. / Chevreau, C. / Gravis, G. / Zanetta, S. / Theodore, C. / Jimenez, M. / Sevin, E. / Laguerre, B. et al. | 2015
- 1128
-
Hypertension and angiotensin system inhibitors: impact on outcome in sunitinib-treated patients for metastatic renal cell carcinomaIzzedine, H. / Derosa, L. / Le Teuff, G. / Albiges, L. / Escudier, B. et al. | 2015
- 1134
-
Tecemotide in unresectable stage III non-small-cell lung cancer in the phase III START study: updated overall survival and biomarker analysesMitchell, P. / Thatcher, N. / Socinski, M. A. / Wasilewska-Tesluk, E. / Horwood, K. / Szczesna, A. / Martín, C. / Ragulin, Y. / Zukin, M. / Helwig, C. et al. | 2015
- 1142
-
A genetic variation in microRNA target site of KRT81 gene is associated with survival in early-stage non-small-cell lung cancerLee, S. Y. / Choi, J. E. / Jeon, H. S. / Hong, M. J. / Choi, Y. Y. / Kang, H. G. / Yoo, S. S. / Lee, E. B. / Jeong, J. Y. / Lee, W. K. et al. | 2015
- 1149
-
No clear effect of postoperative radiotherapy on survival of breast cancer patients with one to three positive nodes: a population-based studyNordenskjöld, A. E. / Fohlin, H. / Albertsson, P. / Arnesson, L. G. / Chamalidou, C. / Einbeigi, Z. / Holmberg, E. / Nordenskjöld, B. / Karlsson, P. et al. | 2015
- 1155
-
Disseminated tumor cells from the bone marrow of patients with nonmetastatic primary breast cancer are predictive of locoregional relapseHartkopf, A. D. / Wallwiener, M. / Fehm, T. N. / Hahn, M. / Walter, C. B. / Gruber, I. / Brucker, S. Y. / Taran, F. A. et al. | 2015
- 1161
-
Survival in stage I–III breast cancer patients by surgical treatment in a publicly funded health care systemFisher, S. / Gao, H. / Yasui, Y. / Dabbs, K. / Winget, M. et al. | 2015
- 1170
-
Phase II study of interim PET–CT-guided response-adapted therapy in advanced Hodgkin's lymphomaGanesan, P. / Rajendranath, R. / Kannan, K. / Radhakrishnan, V. / Ganesan, T. S. / Udupa, K. / Lakshmipathy, K. M. / Mahajan, V. / Sundersingh, S. / Rajaraman, S. et al. | 2015
- 1175
-
Patients with mantle cell lymphoma failing ibrutinib are unlikely to respond to salvage chemotherapy and have poor outcomesCheah, C. Y. / Chihara, D. / Romaguera, J. E. / Fowler, N. H. / Seymour, J. F. / Hagemeister, F. B. / Champlin, R. E. / Wang, M. L. et al. | 2015
- 1180
-
A personalised medicine approach for ponatinib-resistant chronic myeloid leukaemiaKorfi, K. / Mandal, A. / Furney, S. J. / Wiseman, D. / Somervaille, T. C. / Marais, R. et al. | 2015
- 1188
-
Early tumor shrinkage and depth of response predict long-term outcome in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab: results from phase III TRIBE trial by the Gruppo Oncologico del Nord OvestCremolini, C. / Loupakis, F. / Antoniotti, C. / Lonardi, S. / Masi, G. / Salvatore, L. / Cortesi, E. / Tomasello, G. / Spadi, R. / Zaniboni, A. et al. | 2015
- 1194
-
A randomized, placebo-controlled phase III trial of masitinib plus gemcitabine in the treatment of advanced pancreatic cancerDeplanque, G. / Demarchi, M. / Hebbar, M. / Flynn, P. / Melichar, B. / Atkins, J. / Nowara, E. / Moyé, L. / Piquemal, D. / Ritter, D. et al. | 2015
- 1201
-
Effectiveness of bevacizumab added to standard chemotherapy in metastatic colorectal cancer: final results for first-line treatment from the ITACa randomized clinical trialPassardi, A. / Nanni, O. / Tassinari, D. / Turci, D. / Cavanna, L. / Fontana, A. / Ruscelli, S. / Mucciarini, C. / Lorusso, V. / Ragazzini, A. et al. | 2015
- 1208
-
Postoperative irinotecan in resected stage II–III rectal cancer: final analysis of the French R98 Intergroup trial†Delbaldo, C. / Ychou, M. / Zawadi, A. / Douillard, J. Y. / André, T. / Guerin-Meyer, V. / Rougier, P. / Dupuis, O. / Faroux, R. / Jouhaud, A. et al. | 2015
- 1216
-
Genomic alterations in head and neck squamous cell carcinoma determined by cancer gene-targeted sequencingChung, C. H. / Guthrie, V. B. / Masica, D. L. / Tokheim, C. / Kang, H. / Richmon, J. / Agrawal, N. / Fakhry, C. / Quon, H. / Subramaniam, R. M. et al. | 2015
- 1223
-
Phase I trial of everolimus in combination with thoracic radiotherapy in non-small-cell lung cancerDeutsch, E. / Le Péchoux, C. / Faivre, L. / Rivera, S. / Tao, Y. / Pignon, J. P. / Angokai, M. / Bahleda, R. / Deandreis, D. / Angevin, E. et al. | 2015
- 1230
-
Phase I study of every 2- or 3-week dosing of ramucirumab, a human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2 in patients with advanced solid tumorsChiorean, E. G. / Hurwitz, H. I. / Cohen, R. B. / Schwartz, J. D. / Dalal, R. P. / Fox, F. E. / Gao, L. / Sweeney, C. J. et al. | 2015
- 1238
-
Radiosensitization by BRAF inhibitor therapy—mechanism and frequency of toxicity in melanoma patientsHecht, M. / Zimmer, L. / Loquai, C. / Weishaupt, C. / Gutzmer, R. / Schuster, B. / Gleisner, S. / Schulze, B. / Goldinger, S. M. / Berking, C. et al. | 2015
- 1244
-
The impact of docetaxel-related toxicities on health-related quality of life in patients with metastatic cancer (QoliTax)Al-Batran, S. E. / Hozaeel, W. / Tauchert, F. K. / Hofheinz, R. D. / Hinke, A. / Windemuth-Kieselbach, C. / Hübner, A. / Burmester, M. / Koenigsmann, M. / Wiegand, J. et al. | 2015
- 1248
-
Aprepitant versus metoclopramide, both combined with dexamethasone, for the prevention of cisplatin-induced delayed emesis: a randomized, double-blind studyRoila, F. / Ruggeri, B. / Ballatori, E. / Fatigoni, S. / Caserta, C. / Licitra, L. / Mirabile, A. / Ionta, M. T. / Massidda, B. / Cavanna, L. et al. | 2015
- 1254
-
Dynamic prediction in breast cancer: proving feasibility in clinical practice using the TEAM trialFontein, D. B. / Klinten Grand, M. / Nortier, J. W. / Seynaeve, C. / Meershoek-Klein Kranenbarg, E. / Dirix, L. Y. / van de Velde, C. J. / Putter, H. et al. | 2015
- 1263
-
Life expectancy of colon, breast, and testicular cancer patients: an analysis of US-SEER population-based dataCapocaccia, R. / Gatta, G. / Dal Maso, L. et al. | 2015
- 1269
-
Reply to the letter to the editor ‘Patients' preference and informed consent’ by Pumo et al.Pivot, X. / Machackova, Z. et al. | 2015
- 1269
-
Patients' preference and informed consentPumo, V. / Di Mari, A. / Rametta Giuliano, S. / Bordonaro, S. / Lanteri, E. / Tralongo, P. et al. | 2015
- 1270
-
Concomitant ALK translocation and other non-EGFR gene in NSCLC: knowledge in the makingPassaro, A. / Barberis, M. / Catania, C. / Pessina, S. / de Marinis, F. et al. | 2015
- 1272
-
Reply to the letter to the editor ‘Potential clinical relevant drug–drug interactions: comparison between different compendia, do we have a validated method?’ by Conde-Estévez et al.van Leeuwen, R. W. / Mathijssen, R. H. / Jansman, F. G. / van Gelder, T. et al. | 2015
- 1272
-
Potential clinical relevant drug–drug interactions: comparison between different compendia, do we have a validated method?Conde-Estévez, D. / Echeverría-Esnal, D. / Tusquets, I. / Albanell, J. et al. | 2015
- 1274
-
Denosumab for the prevention of skeletal complications in metastatic castration-resistant prostate cancer: comparison of skeletal-related events and symptomatic skeletal events| 2015